New Delhi, April 4 -- Pharma stocks witnessed a sharp decline on Friday after US President Donald Trump hinted at upcoming tariffs on pharmaceutical imports. The Nifty Pharma index tumbled over 6%, with major Indian pharma companies taking a hit.

Despite this setback, stock market experts believe the sector remains attractive for long-term investors. With India supplying a significant portion of US generic drugs, the industry's resilience and growth prospects continue to offer opportunities.

Three of the top Indian pharma stocks - Sun Pharmaceutical Industries, Dr Reddy's Laboratories and Lupin - were also trading lower on April 4. Sun Pharma share price plunged as much as 6.33%, Dr Reddy's shares dropped 6.5%, while Lupin stock price c...